MariMed Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

MEZZANINE EQUITY (Details Narrative)

MEZZANINE EQUITY (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended	6 Months Ended
MEZZANINE EQUITY (Details Narrative) - USD ($)	Feb. 29, 2020	Mar. 31, 2021	Feb. 29, 2020	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Entity Listings [Line Items]
Stock Issued During Period, Value, New Issues
Proceeds from Issuance or Sale of Equity		$ 23,000,000.0
Payments for Construction in Process		$ 7,800,000
Company owned and managed facilities during period					$ 6,600,000
Targeted acquisition commitment description		The balance of the committed facility of up to an additional $23.0 million is intended to fund the Company’s specific targeted acquisitions provided such acquisitions are contracted in 2021 and consummated, including obtaining the necessary regulatory approvals, no later than the end of 2022
Warrants Two [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					15,540,540
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.087
Fair Value Adjustment of Warrants				$ 9,500,000	$ 9,500,000
Maximum [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5.50
Minimum [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.11
Hadron Healthcare Master Fund [Member] \| Warrants [Member]
Entity Listings [Line Items]
Number of common stock issued during period		6,216,216
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.087		$ 1.087
Stock issuance costs		$ 387,000
Hadron Healthcare Master Fund [Member] \| Maximum [Member] \| Warrants [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		15,540,540		15,540,540
3M Note [Member]
Entity Listings [Line Items]
Repayments of Debt and Lease Obligation					$ 15,200,000
Series B Convertible Preferred Stock [Member] \| Volume Weighted Average Price of Common Stock [Member]
Entity Listings [Line Items]
Preferred Stock, Convertible, Conversion Price	$ 4.00		$ 4.00
Number of trading days, description			least twenty consecutive trading days
Series B preferred stock conversion price, description	If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option		If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share.
Series B Holders [Member]
Entity Listings [Line Items]
Shares Issued, Price Per Share	$ 3.00		$ 3.00
Preferred Stock, Convertible, Conversion Price	3.00		$ 3.00
Series C Convertible Preferred Stock [Member] \| Minimum [Member]
Entity Listings [Line Items]
Outstanding percentage.		50.00%
Exchange Agreement [Member] \| Two Institutional Shareholders [Member] \| Series B Convertible Preferred Stock [Member]
Entity Listings [Line Items]
Stock Issued During Period Shares Exchanged			4,908,333
Shares Issued, Price Per Share	$ 3.00		$ 3.00
Treasury Stock Acquired, Average Cost Per Share			$ 3.00
Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member]
Entity Listings [Line Items]
Shares Issued, Price Per Share		$ 3.70		$ 3.70
Stock Issued During Period, Value, New Issues		$ 23,000,000.0
Warrants and Rights Outstanding, Term		4 years		4 years
Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member] \| Maximum [Member]
Entity Listings [Line Items]
Number of shares exchanged value.		$ 46,000,000.0